 Anna Malykhina
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder | 30 | 2023 | 162 | 7.280 |
Why?
| | Lower Urinary Tract Symptoms | 10 | 2022 | 47 | 3.650 |
Why?
| | Urinary Bladder, Overactive | 10 | 2021 | 20 | 2.710 |
Why?
| | Urination | 10 | 2022 | 40 | 2.670 |
Why?
| | Potassium Channels, Tandem Pore Domain | 4 | 2019 | 12 | 2.300 |
Why?
| | Muscle Contraction | 13 | 2019 | 389 | 2.140 |
Why?
| | Muscle, Smooth | 9 | 2017 | 144 | 2.000 |
Why?
| | Urinary Bladder, Neurogenic | 4 | 2022 | 30 | 1.880 |
Why?
| | Multiple Sclerosis | 6 | 2022 | 376 | 1.670 |
Why?
| | Pelvic Pain | 3 | 2022 | 32 | 1.580 |
Why?
| | Colon | 7 | 2014 | 233 | 1.530 |
Why?
| | TRPV Cation Channels | 6 | 2021 | 31 | 1.500 |
Why?
| | Coronavirus Infections | 3 | 2022 | 330 | 1.360 |
Why?
| | Sensory Receptor Cells | 3 | 2022 | 77 | 1.220 |
Why?
| | Urinary Bladder Diseases | 5 | 2019 | 18 | 1.180 |
Why?
| | Cystitis, Interstitial | 4 | 2014 | 16 | 1.010 |
Why?
| | Murine hepatitis virus | 3 | 2022 | 15 | 0.990 |
Why?
| | Protein Kinase C | 3 | 2015 | 273 | 0.980 |
Why?
| | Urinary Bladder Neck Obstruction | 4 | 2023 | 20 | 0.890 |
Why?
| | Colitis | 7 | 2014 | 223 | 0.870 |
Why?
| | Mice, Inbred C57BL | 13 | 2022 | 4694 | 0.800 |
Why?
| | Lumbosacral Region | 1 | 2022 | 46 | 0.770 |
Why?
| | Urinary Tract Infections | 2 | 2014 | 134 | 0.760 |
Why?
| | Pain Perception | 1 | 2022 | 37 | 0.750 |
Why?
| | Neuronal Plasticity | 2 | 2013 | 209 | 0.730 |
Why?
| | Administration, Intravesical | 3 | 2017 | 14 | 0.730 |
Why?
| | Receptor, Muscarinic M3 | 1 | 2020 | 3 | 0.720 |
Why?
| | Receptor, Adenosine A1 | 1 | 2020 | 11 | 0.710 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2020 | 15 | 0.710 |
Why?
| | Nociception | 1 | 2020 | 17 | 0.710 |
Why?
| | Calcitonin Gene-Related Peptide | 4 | 2016 | 31 | 0.700 |
Why?
| | Analgesics | 1 | 2022 | 158 | 0.700 |
Why?
| | Substance P | 4 | 2016 | 44 | 0.690 |
Why?
| | Animals | 35 | 2023 | 31709 | 0.680 |
Why?
| | Coronavirus | 3 | 2022 | 40 | 0.670 |
Why?
| | Hyperalgesia | 1 | 2020 | 107 | 0.670 |
Why?
| | Neuroglia | 1 | 2020 | 150 | 0.660 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2019 | 51 | 0.640 |
Why?
| | Chronic Pain | 1 | 2022 | 210 | 0.610 |
Why?
| | Inflammation | 5 | 2020 | 2480 | 0.600 |
Why?
| | Urodynamics | 5 | 2019 | 28 | 0.570 |
Why?
| | Urethra | 1 | 2017 | 48 | 0.570 |
Why?
| | Mice | 18 | 2023 | 14872 | 0.570 |
Why?
| | Urogenital System | 1 | 2016 | 18 | 0.530 |
Why?
| | Urinary Tract | 1 | 2016 | 36 | 0.520 |
Why?
| | Phenotype | 3 | 2019 | 2797 | 0.520 |
Why?
| | Cannabinoids | 1 | 2017 | 115 | 0.510 |
Why?
| | Diterpenes | 2 | 2012 | 31 | 0.510 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2022 | 498 | 0.500 |
Why?
| | Encephalomyelitis | 1 | 2014 | 9 | 0.470 |
Why?
| | Marijuana Use | 1 | 2017 | 167 | 0.460 |
Why?
| | Male | 31 | 2023 | 55609 | 0.460 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 182 | 0.460 |
Why?
| | Estrous Cycle | 1 | 2014 | 14 | 0.460 |
Why?
| | Cystitis | 1 | 2014 | 20 | 0.460 |
Why?
| | Ganglia, Spinal | 5 | 2014 | 41 | 0.460 |
Why?
| | Disease Models, Animal | 12 | 2022 | 3535 | 0.450 |
Why?
| | Neuropeptides | 1 | 2014 | 65 | 0.450 |
Why?
| | Demyelinating Diseases | 1 | 2014 | 75 | 0.440 |
Why?
| | Rats, Sprague-Dawley | 8 | 2015 | 2218 | 0.430 |
Why?
| | Cyclic Nucleotide-Gated Cation Channels | 2 | 2010 | 21 | 0.430 |
Why?
| | Penis | 1 | 2013 | 37 | 0.420 |
Why?
| | Erectile Dysfunction | 1 | 2013 | 38 | 0.420 |
Why?
| | Viscera | 1 | 2012 | 15 | 0.420 |
Why?
| | Neural Pathways | 1 | 2014 | 261 | 0.410 |
Why?
| | Peripheral Nerves | 1 | 2012 | 64 | 0.410 |
Why?
| | Colonic Diseases | 1 | 2012 | 25 | 0.390 |
Why?
| | Trinitrobenzenesulfonic Acid | 5 | 2012 | 9 | 0.370 |
Why?
| | Motor Neurons | 1 | 2012 | 213 | 0.360 |
Why?
| | Color Vision Defects | 1 | 2010 | 6 | 0.340 |
Why?
| | Rats | 8 | 2014 | 4958 | 0.340 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2010 | 14 | 0.340 |
Why?
| | Neurons | 3 | 2013 | 1280 | 0.340 |
Why?
| | Doxorubicin | 2 | 2021 | 285 | 0.320 |
Why?
| | Biomarkers | 3 | 2017 | 3408 | 0.320 |
Why?
| | Protein Subunits | 1 | 2010 | 201 | 0.320 |
Why?
| | Calcium Channels | 3 | 2021 | 145 | 0.290 |
Why?
| | Central Nervous System | 2 | 2022 | 235 | 0.280 |
Why?
| | Pons | 2 | 2017 | 30 | 0.270 |
Why?
| | Mice, Transgenic | 3 | 2022 | 1950 | 0.270 |
Why?
| | Lactams, Macrocyclic | 2 | 2017 | 46 | 0.270 |
Why?
| | Benzoquinones | 2 | 2017 | 44 | 0.270 |
Why?
| | Female | 20 | 2022 | 59523 | 0.260 |
Why?
| | Mutation | 3 | 2010 | 3346 | 0.240 |
Why?
| | Vincristine | 2 | 2022 | 98 | 0.230 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2016 | 106 | 0.230 |
Why?
| | Humans | 26 | 2022 | 114709 | 0.230 |
Why?
| | Channelopathies | 1 | 2004 | 5 | 0.230 |
Why?
| | Physical Stimulation | 2 | 2014 | 77 | 0.220 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 797 | 0.210 |
Why?
| | Tocotrienols | 1 | 2023 | 3 | 0.210 |
Why?
| | Receptors, Muscarinic | 2 | 2018 | 17 | 0.210 |
Why?
| | Muscarinic Agonists | 2 | 2020 | 9 | 0.210 |
Why?
| | Fluorescent Antibody Technique | 2 | 2022 | 397 | 0.200 |
Why?
| | Signal Transduction | 6 | 2021 | 4516 | 0.190 |
Why?
| | Gastrointestinal Tract | 1 | 2004 | 169 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2087 | 0.190 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 120 | 0.180 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 314 | 0.180 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2021 | 19 | 0.180 |
Why?
| | Benzilates | 1 | 2020 | 1 | 0.180 |
Why?
| | Nortropanes | 1 | 2020 | 1 | 0.180 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 2020 | 7 | 0.180 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2020 | 8 | 0.180 |
Why?
| | Genes, Synthetic | 1 | 2020 | 14 | 0.180 |
Why?
| | Xanthines | 1 | 2020 | 15 | 0.180 |
Why?
| | Freund's Adjuvant | 1 | 2020 | 17 | 0.180 |
Why?
| | Clozapine | 1 | 2020 | 19 | 0.180 |
Why?
| | Touch | 1 | 2020 | 30 | 0.180 |
Why?
| | Theophylline | 1 | 2020 | 60 | 0.180 |
Why?
| | Mice, Knockout | 2 | 2019 | 2570 | 0.170 |
Why?
| | Constipation | 1 | 2021 | 76 | 0.170 |
Why?
| | RNA-Binding Proteins | 1 | 2022 | 345 | 0.170 |
Why?
| | Comorbidity | 2 | 2016 | 1448 | 0.170 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1518 | 0.170 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 7 | 0.160 |
Why?
| | Muscle Relaxation | 1 | 2019 | 19 | 0.160 |
Why?
| | Neurons, Afferent | 2 | 2012 | 85 | 0.160 |
Why?
| | Myosin Light Chains | 1 | 2019 | 26 | 0.160 |
Why?
| | Gene Frequency | 2 | 2018 | 477 | 0.160 |
Why?
| | Hot Temperature | 1 | 2020 | 302 | 0.160 |
Why?
| | Receptors, Purinergic P2X1 | 1 | 2018 | 4 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 194 | 0.160 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 109 | 0.150 |
Why?
| | Cholinergic Fibers | 1 | 2018 | 16 | 0.150 |
Why?
| | White Matter | 1 | 2019 | 105 | 0.150 |
Why?
| | Spinal Cord | 2 | 2014 | 347 | 0.150 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 616 | 0.150 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2019 | 351 | 0.140 |
Why?
| | Caveolins | 1 | 2017 | 5 | 0.140 |
Why?
| | Cancer Survivors | 1 | 2021 | 205 | 0.140 |
Why?
| | Postmenopause | 2 | 2016 | 303 | 0.140 |
Why?
| | Urinary Incontinence, Urge | 1 | 2017 | 2 | 0.140 |
Why?
| | Lumbosacral Plexus | 2 | 2017 | 6 | 0.140 |
Why?
| | Brain Stem | 1 | 2017 | 101 | 0.140 |
Why?
| | Age Factors | 4 | 2019 | 2894 | 0.140 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 17 | 0.140 |
Why?
| | Pilot Projects | 2 | 2019 | 1373 | 0.130 |
Why?
| | Reflex | 2 | 2018 | 64 | 0.130 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 40 | 0.130 |
Why?
| | Nerve Growth Factor | 1 | 2016 | 27 | 0.130 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 1131 | 0.130 |
Why?
| | Cytoskeleton | 1 | 2017 | 176 | 0.130 |
Why?
| | Electric Stimulation | 3 | 2012 | 250 | 0.130 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 347 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 610 | 0.120 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 2015 | 8 | 0.120 |
Why?
| | Phorbol Esters | 1 | 2015 | 15 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2017 | 236 | 0.120 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2540 | 0.120 |
Why?
| | RNA, Small Interfering | 1 | 2017 | 535 | 0.120 |
Why?
| | Pituitary-Adrenal System | 1 | 2016 | 130 | 0.120 |
Why?
| | Down-Regulation | 1 | 2017 | 594 | 0.120 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2016 | 164 | 0.120 |
Why?
| | Brain Diseases | 1 | 2016 | 125 | 0.120 |
Why?
| | Pyuria | 1 | 2014 | 2 | 0.120 |
Why?
| | Bacteriuria | 1 | 2014 | 8 | 0.120 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1629 | 0.110 |
Why?
| | Urologic Diseases | 1 | 2014 | 35 | 0.110 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 225 | 0.110 |
Why?
| | Nerve Growth Factors | 1 | 2014 | 71 | 0.110 |
Why?
| | Carbachol | 2 | 2011 | 21 | 0.110 |
Why?
| | Adult | 7 | 2019 | 30554 | 0.110 |
Why?
| | Peroxidase | 1 | 2014 | 163 | 0.110 |
Why?
| | Genotype | 1 | 2018 | 1760 | 0.110 |
Why?
| | Potassium Channels | 1 | 2014 | 121 | 0.110 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2012 | 4 | 0.110 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 1 | 2012 | 10 | 0.110 |
Why?
| | Afferent Pathways | 1 | 2013 | 42 | 0.110 |
Why?
| | Case-Control Studies | 3 | 2019 | 3004 | 0.100 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 124 | 0.100 |
Why?
| | Cholinergic Neurons | 1 | 2012 | 15 | 0.100 |
Why?
| | Blotting, Western | 2 | 2012 | 1147 | 0.100 |
Why?
| | Organ Culture Techniques | 1 | 2013 | 140 | 0.100 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1016 | 0.100 |
Why?
| | Cytokines | 1 | 2019 | 1841 | 0.100 |
Why?
| | Proteomics | 1 | 2017 | 836 | 0.100 |
Why?
| | Premenopause | 1 | 2011 | 106 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 1880 | 0.090 |
Why?
| | Cholinergic Agents | 1 | 2011 | 15 | 0.090 |
Why?
| | Sex Factors | 1 | 2016 | 1715 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2012 | 321 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 1842 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4411 | 0.090 |
Why?
| | Neuralgia | 1 | 2011 | 122 | 0.090 |
Why?
| | Incidence | 1 | 2016 | 2313 | 0.090 |
Why?
| | Mutant Proteins | 1 | 2010 | 95 | 0.080 |
Why?
| | Ion Channel Gating | 1 | 2010 | 83 | 0.080 |
Why?
| | Prospective Studies | 5 | 2021 | 6220 | 0.080 |
Why?
| | Models, Animal | 1 | 2011 | 344 | 0.080 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 262 | 0.080 |
Why?
| | Recurrence | 1 | 2011 | 935 | 0.080 |
Why?
| | Middle Aged | 7 | 2019 | 26738 | 0.080 |
Why?
| | Prognosis | 1 | 2016 | 3330 | 0.080 |
Why?
| | Acute Disease | 1 | 2011 | 911 | 0.080 |
Why?
| | Protein Transport | 1 | 2010 | 395 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2016 | 944 | 0.080 |
Why?
| | Brain | 1 | 2019 | 2371 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 923 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 668 | 0.070 |
Why?
| | Neoplasms | 1 | 2021 | 2097 | 0.070 |
Why?
| | HEK293 Cells | 1 | 2010 | 591 | 0.070 |
Why?
| | Hypertrophy | 2 | 2019 | 109 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 2968 | 0.070 |
Why?
| | src-Family Kinases | 2 | 2007 | 88 | 0.070 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2006 | 24 | 0.070 |
Why?
| | Trinucleotide Repeats | 1 | 2006 | 24 | 0.070 |
Why?
| | Iron-Binding Proteins | 1 | 2006 | 38 | 0.070 |
Why?
| | Tyrosine | 1 | 2007 | 214 | 0.070 |
Why?
| | Irritable Bowel Syndrome | 1 | 2006 | 29 | 0.070 |
Why?
| | Sacrum | 1 | 2005 | 65 | 0.060 |
Why?
| | Aged | 4 | 2017 | 19074 | 0.060 |
Why?
| | Cerebellum | 1 | 2006 | 200 | 0.060 |
Why?
| | Quality of Life | 2 | 2011 | 2353 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2007 | 395 | 0.060 |
Why?
| | Lumbar Vertebrae | 1 | 2005 | 210 | 0.060 |
Why?
| | Action Potentials | 1 | 2006 | 406 | 0.050 |
Why?
| | Ion Channels | 1 | 2004 | 123 | 0.050 |
Why?
| | Electrophysiology | 3 | 2010 | 201 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2553 | 0.050 |
Why?
| | Child, Preschool | 1 | 2016 | 9119 | 0.050 |
Why?
| | Child | 2 | 2021 | 18422 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2019 | 1144 | 0.050 |
Why?
| | Models, Biological | 2 | 2010 | 1621 | 0.050 |
Why?
| | Administration, Oral | 1 | 2023 | 728 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2022 | 413 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 9 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 9 | 0.040 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 19 | 0.040 |
Why?
| | Anxiety, Separation | 1 | 2018 | 16 | 0.040 |
Why?
| | Maternal Deprivation | 1 | 2018 | 15 | 0.040 |
Why?
| | Risk Factors | 1 | 2011 | 8634 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3053 | 0.030 |
Why?
| | Young Adult | 1 | 2011 | 10472 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 778 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2011 | 12556 | 0.030 |
Why?
| | Bethanechol | 1 | 2014 | 1 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1569 | 0.030 |
Why?
| | Atropine | 1 | 2014 | 25 | 0.030 |
Why?
| | Muscarinic Antagonists | 1 | 2014 | 25 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 4624 | 0.030 |
Why?
| | Time Factors | 2 | 2019 | 6116 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2016 | 267 | 0.030 |
Why?
| | Health Surveys | 1 | 2016 | 443 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 4410 | 0.030 |
Why?
| | Adolescent | 1 | 2011 | 17855 | 0.030 |
Why?
| | Phenanthrenes | 1 | 2012 | 10 | 0.030 |
Why?
| | Carboxylic Acids | 1 | 2012 | 26 | 0.030 |
Why?
| | Calcium | 2 | 2010 | 1108 | 0.030 |
Why?
| | Heart Rate | 1 | 2016 | 709 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2014 | 430 | 0.030 |
Why?
| | Catastrophization | 1 | 2011 | 8 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2012 | 138 | 0.020 |
Why?
| | Intestinal Diseases | 1 | 2011 | 33 | 0.020 |
Why?
| | Adaptation, Psychological | 1 | 2016 | 547 | 0.020 |
Why?
| | Rabbits | 1 | 2012 | 733 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2010 | 135 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 840 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 750 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 318 | 0.020 |
Why?
| | Protein Stability | 1 | 2010 | 157 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2010 | 325 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 304 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2010 | 502 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1134 | 0.020 |
Why?
| | Cholinergic Agonists | 1 | 2007 | 7 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2007 | 32 | 0.020 |
Why?
| | Nitric Acid | 1 | 2007 | 5 | 0.020 |
Why?
| | Enema | 1 | 2007 | 38 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2007 | 108 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1230 | 0.020 |
Why?
| | Escherichia coli | 1 | 2010 | 720 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6347 | 0.020 |
Why?
| | Dextran Sulfate | 1 | 2005 | 70 | 0.020 |
Why?
| | Friedreich Ataxia | 1 | 2006 | 64 | 0.020 |
Why?
| | Cell Line | 1 | 2010 | 2637 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 789 | 0.010 |
Why?
| | Recovery of Function | 1 | 2007 | 574 | 0.010 |
Why?
|
|
Malykhina's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|